Evidence map›Paper›PMID 41088468›Full record

ArticleThe journal of obstetrics and gynaecology research2025

Long Term Disease Control of Brain Metastases From Chemotherapy-Resistant Endometrial Cancer With Lenvatinib and Pembrolizumab: A Case Report.

Ayaka Fujioka, Akimasa Takahashi, Tsukuru Amano, Yuji Tanaka, Yutaka Yoneoka, Shunichiro Tsuji

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in The journal of obstetrics and gynaecology research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Ayaka FujiokaDepartment of Obstetrics and Gynecology, Shiga University of Medical Sciences, Otsu, Japan.
Akimasa TakahashiDepartment of Obstetrics and Gynecology, Shiga University of Medical Sciences, Otsu, Japan.ORCID https://orcid.org/0000-0001-5698-553X
Tsukuru AmanoDepartment of Obstetrics and Gynecology, Shiga University of Medical Sciences, Otsu, Japan.ORCID https://orcid.org/0000-0003-2919-6337
Yuji TanakaDepartment of Obstetrics and Gynecology, Shiga University of Medical Sciences, Otsu, Japan.ORCID https://orcid.org/0000-0002-7045-8151
Yutaka YoneokaDepartment of Obstetrics and Gynecology, Shiga University of Medical Sciences, Otsu, Japan.
Shunichiro TsujiDepartment of Obstetrics and Gynecology, Shiga University of Medical Sciences, Otsu, Japan.ORCID https://orcid.org/0000-0003-3945-6817

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Brain metastases from endometrial carcinoma are extremely rare and associated with poor prognosis. We present a 43-year-old woman with mismatch repair deficient endometrial cancer who developed multiple brain metastases refractory to cytotoxic chemotherapy and without extracranial involvement. After stereotactic radiotherapy, combination therapy with lenvatinib and pembrolizumab resulted in sustained partial remission for 16 months, with no evidence of brain hemorrhage. This case demonstrates that lenvatinib plus pembrolizumab may offer an effective and safe therapeutic option for brain metastases from endometrial cancer, even in patients resistant to conventional therapy. Remarkably, this outcome challenges the traditionally poor prognosis of such cases and underscores the potential for novel targeted and immunotherapeutic strategies to redefine the standard of care for this rare and devastating complication.

Indexed as

Antibodies, Monoclonal, HumanizedAntineoplastic Agents, ImmunologicalBrain NeoplasmsEndometrial NeoplasmsPhenylurea CompoundsQuinolinesAdultDrug Resistance, NeoplasmFemaleHumansAntibodies, Monoclonal, HumanizedAntineoplastic Agents, ImmunologicallenvatinibpembrolizumabPhenylurea CompoundsQuinolinesbrain metastasesendometrial cancerlenvatinibpembrolizumabtargeted therapy

Identifiers

PMID41088468
PMCPMC12521617

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.